Table 3.

Changes in plasma lipid, lipoprotein, and CRP levels, and coronary atherosclerosis progression in the placebo and the HRT arms of the ERA study by diabetes status.

	No diabetes			Diabetes			P*(treatment)	P*(diabetes)	P***(interaction)
	Placebo (N=59)	HRT (N=123)	effect size d	Placebo (N=27)	HRT (N=41)	effect size d
TC, mg/dl	3.2 (37)	−11.6 (40)	0.38	−1.9 (30	−7.5 (37)	0.16	0.02	0.69	0.45
LDL-C, mg/dl	−0.2 (31)	−18.5 (39)	0.52	7 (21)	−14.5 (42)	0.64	0.0001	0.13	0.86
TG, mg/dl	6.7 (89)	1.4 (69)	0.07	7.0 (128)	20.5 (124)	−0.11	0.86	0.12	0.43
RLP-C, mg/dl	1.7 (9)	−2.3 (6.2)	0.53	−0.6 (8)	−2.6 (10.1)	0.22	0.001	0.64	0.42
Apo C-III, mg/dl	0.3 (3.4)	−0.2 (3.3)	0.15	−0.2 (3.3)	0.6 (4.3)	−0.21	0.96	0.76	0.15
HDL-C, mg/dl	1.8 (7)	7.7 (8.9)	−0.74	0.4 (6)	4.6 (7.2)	−0.63	0.0001	0.02	0.38
Apo A-I, mg/dl	1.8 (17)	19.5 (20)	−0.95	1.2 (12)	13.9 (18)	−0.83	0.0001	0.14	0.21
HDL subpopulations, mg/dl
pre-β1	−1.1 (6.8)	1.5 (6.4)	−0.39	−2.0 (7.2)	2.7 (7.5)	−0.64	0.0001	0.63	0.39
pre-β2	−0.1 (0.7)	0.2 (0.8)	−0.40	0.2 (1.0)	0.3 (1.1)	−0.10	0.06	0.33	0.38
α1	0.5 (4.5)	6.5 (7.2)	−0.99	2.3 (5.4)	3.9 (8.3)	−0.23	0.0001	0.38	0.02
α2	0.4 (8.4)	7.0 (9.1)	−1.07	0.8 (5.9)	2.7 (8.7)	−0.26	0.0001	0.07	0.06
α3	0.4 (7.9)	2.4 (7.5)	−0.26	−0.9 (7.2)	2.9 (7.8)	−0.50	0.02	0.70	0.63
pre-α1	0.2 (1.4)	1.1 (1.6)	−0.60	0.5 (1.5)	0.8 (1.8)	−0.18	0.0001	0.65	0.09
pre-α2	0.6 (1.5)	0.9 (1.4)	−0.21	0.2 (1.7)	0.4 (1.7)	−0.12	0.14	0.03	0.86
pre-α3	0.5 (1.9)	−0.1 (1.5)	0.35	0.1 (2.0)	0.0 (1.9)	0.05	0.04	0.53	0.37
CRP, mg/dl	−0.05 (1.43)	0.38 (1.10)	−0.34	−0.18 (0.54)	0.06 (0.58)	−0.48	0.01	0.08	0.52
	(N=49)	(N=108)		(N=22)	(N=37)
mean min lumen diameter, mm	−0.09 (0.19)	−0.08 (0.18)	−0.05	−0.19 (0.18)	−0.14 (0.26)	−0.22	0.44	0.04	0.46

Mean(SD)

Effect size: Cohen’s d

^*P value for treatment effect, model adjusted for age, race, smoking, and use of lipid-lowering medications

^**P value for diabetes effect, model as above

^***P value for the interaction between treatment and diabetes, model as above